Cassava Sciences, Inc. announced that the Board of Directors has appointed Richard (Rick) Barry as the Company?s principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO.
Mr. Barry succeeds Remi Barbier, the Company?s CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a non-executive capacity, without duties or responsibilities. Mr. Barry has served as a director of Cassava since June 2021. Since June 2015, Mr. Barry has also served as Director of Sarepta Therapeutics, Inc., and from June 2019 through October 2020, he served as a director of MiMedx Group Inc. He has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. He holds a Bachelor of Arts from Pennsylvania State University.